InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,572.85
(
0.00%
)
US TECH 100
19,943.60
(
0.25%
)
Dow Jones
39,344.79
(
0.00%
)
Brent Oil
84.96
(
-0.54%
)
Bitcoin
57,288.72
(
1.03%
)
Post# of 252526
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 831
Posts 119993
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 94041

Tuesday, 04/13/2010 9:42:05 AM

Tuesday, April 13, 2010 9:42:05 AM

Post# of 252526
TEVA:

Leader Capital Markets analyst Yoav Burgan said, “This is another milestone in Teva's strategic plan to develop a pipeline of brand drugs. Teva's primary objective is to reduce its dependence on Copaxone over time and to gradually change its business mix toward brand drugs.”

That’s an odd thing for an analyst to write; Teva’s own publicly stated goal is to maintain the same mix of generic (70%) and branded (30%) sales that it has today.


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up